Cargando…

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas

INTRODUCTION: The emergence of new omics approaches, such as genomic algorithms to identify tumor mutations and molecular modeling tools to predict the three-dimensional structure of proteins, has facilitated the understanding of the dynamic mechanisms involved in the pathogenesis of low-grade gliom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bendahou, Mohammed Amine, Arrouchi, Housna, Lakhlili, Wiame, Allam, Loubna, Aanniz, Tarik, Cherradi, Nadia, Ibrahimi, Azeddine, Boutarbouch, Mahjouba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160765/ https://www.ncbi.nlm.nih.gov/pubmed/32313423 http://dx.doi.org/10.1177/1176935120915839

Ejemplares similares

A review on PIM kinases in tumors
por: Arrouchi, Housna, et al.
Publicado: (2019)

Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
por: Arrouchi, Housna, et al.
Publicado: (2019)

Bioinformatics Analysis of Differentially Expressed Genes and miRNAs in Low-Grade Gliomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

AKT1 Polymorphism (rs10138227) and Risk of Colorectal Cancer in Moroccan Population: A Case Control Study
por: Allam, Loubna, et al.
Publicado: (2020)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

Structure–activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches
por: Lakhlili, Wiame, et al.
Publicado: (2016)

Molecular screening and docking analysis of LMTK3and AKT1 combined inhibitors
por: Allam, Loubna, et al.
Publicado: (2018)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Determination and validation of mTOR kinase-domain 3D structure by homology modeling
por: Lakhlili, Wiame, et al.
Publicado: (2015)

Docking analysis of verteporfin with YAP WW domain
por: Kandoussi, Ilham, et al.
Publicado: (2017)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Significant Association of Polymorphisms in the TCF7L2 Gene with a Higher Risk of Type 2 Diabetes in a Moroccan Population
por: Elhourch, Sarah, et al.
Publicado: (2021)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
por: Kandoussi, Ilham, et al.
Publicado: (2020)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report
por: Agopyan-Miu, Alexander H. C. W., et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

Conventional and emerging treatments of astrocytomas and oligodendrogliomas
por: Kessler, Tobias, et al.
Publicado: (2022)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas
por: Mäkelä, Katri, et al.
Publicado: (2014)

MPC-07 MECHANISMS OF BETTER PROGNOSIS IN IDH-MUTATED ASTROCYTOMA WITH 19Q-LOSS
por: Otani, Ryohei, et al.
Publicado: (2019)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications
por: Marker, Daniel F, et al.
Publicado: (2021)

A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1
por: Klink, Barbara, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3keso0qo7u34ssd3ocs3876fk1